Feature | January 31, 2012 | Mary Beth Nevulis

The Year’s Trends in Digital Mammography

This article appeared as the introduction to a chart on digital mammography systems in the January/February 2012 issue.

The Fuji Aspire FFDM system

Digital mammography (DM) is a field in which advances are constantly being made and new trends evolve. During a scientific session at RSNA 2011, John M. Lewin, M.D., discussed recent trends and how they have changed during the past year.

One trend, Lewin said, was that mammography screening in general is still under attack. Myriad studies have argued for and against mammography, citing false positives, mortality rates, number of life-years gained, bang for the buck (and bang versus buck) and other factors, such as at what age women should be screened, how often they should be screened — and whether they should be screened at all. Lewin has a positive view of mammography screening, referring to “our side” when citing a study indicating that 80 percent of women feel mammograms are vital to their health.

A second trend is about breast density reporting legislation. The facts, Lewin says, are these: Breast density is a risk factor for breast cancer, and mammography is less sensitive in dense breasts. It is still conjecture that adding more tests to mammography will decrease breast cancer mortality rates, but a number of groups (including areyoudense.org) advocate women knowing their breast density.

There is federal legislation in the works requiring radiologists to report breast density. If passed, it would require mammography reporting packages to accommodate breast density in their patient letters about test results. Breast density analysis software would be amped up. Automated whole-breast ultrasound screening would become the norm, with devices that would screen without the radiologist’s involvement, eliminating user variability; the radiologist would simply read a video loop.

Trend No. 3 is having more choices in approved devices, both pre-market approval (PMA) and 510(k), as well as increased concern about radiation. Lewin said not much changed with this over the past year, with radiation concerns focused on computed tomography (CT) and imaging children (where he believes the focus should lie), except for a paper published in 2010 noting the high whole-body radiation dose from sestamibi breast scanning or breast positron emission mammography (PEM). However, dose has since been lowered by improved technology and dual-head units.

Another trend in which not much has changed is new detectors; Lewin said that except for in labs, there really have not been advances here in the past year. One change — Philips purchased Sectra’s mammography system, which uses photon counting or multiple-slit scanning.

Last year, a fifth trend was that mammography moved from 2-D to 3-D in the realms of tomosynthesis and breast CT. Hologic received U.S. Food and Drug Administration (FDA) approval after five years of waiting; the approval is for using tomosynthesis in combination with 2-D mammography. However, using both of these in conjunction almost doubles the dose of a 2-D mammogram, so there is a cost to getting more images and fewer artifacts.

Lewin speculated about eliminating the 2-D view to reduce dose by using something he called a “2-D synthetic view,” in which the tomosynthesis data is used to create a view that simulates a 2-D mammogram and allows one to see calcification distributions that might be difficult to see on tomo slices. He stated that a method like this might allow the FDA’s requirement to be dropped.

Adding contrast is yet another DM trend. The hypothesis behind contrast-enhanced digital mammography (CEDM) is that by using intravenous iodinated contrast with digital mammography, occult cancers can be made visible and breast cancers can appear enhanced on magnetic resonance imaging (MRI) and CT.

However, there are a few stumbling blocks: The contrast resolution of DM is far lower than CT and MRI, and breast compression limits the image to a single view and inhibits blood flow, thus occluding the flow of contrast. As an alternative to CEDM, Lewin named dual-energy subtraction, in which one takes two mammograms of different energies — both of them after the contrast is already in — and uses an algorithm to perform a weighted subtraction. The breast does not need to be immobilized during contrast, only while imaging, and images can be taken one after another until the contrast dissipates.

Another 2011 trend that has not made many new advances is combining exams — for example, mammography plus ultrasound, or mammography plus nuclear imaging, such as positron emission tomography (PET). Lewin said nothing much happened over the last year; automated screening ultrasound continues to proliferate (not necessarily with mammography in direct combination, although that is in the works). But this may not really take off until screening becomes a paid indication under Medicare. 

The eighth and final trend Lewin discussed was tailored screening, which ties into the breast density legislation mentioned above. Breast density legislation will open the floor for even more tailored screening in terms of population — for instance, if there is a way to determine who is more likely to have cancer. However, tailored screening has never been studied in randomized controlled trials, so there is no evidence for or against it.

Lewin named several events to watch for in the coming year. He expects that tomosynethsis will come out with a synthetic 2-D view, so 2-D imaging could be scrapped altogether; that other tomosynthesis units will be approved; that more states will approve breast density legislation; and that contrast mammography will replace MRI in some cases.

Related Content

Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...
Hologic Acquires Digital Specimen Radiography Company Faxitron Bioptics

VisionCT 3-D breast specimen-designated computed tomography (CT) system. Image courtesy of Faxitron Bioptics.

News | Breast Imaging | July 31, 2018
Hologic Inc. announced it has completed the acquisition of Faxitron Bioptics, a privately-held leader in digital...
Konica Minolta Hosting Lunch and Learn at 23rd Annual Mammography Meeting in Santa Fe
News | Breast Imaging | July 31, 2018
Konica Minolta Healthcare Americas Inc. will sponsor a lunch and learn featuring its Exa Mammo platform during the 23rd...
FDA Approves New Tomosynthesis Quality Control Tests for ACR Digital Mammography QC Manual
News | Mammography | July 30, 2018
The U.S. Food and Drug Administration (FDA) recently approved the American College of Radiology’s (ACR’s) amendment to...
The Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal. The FDA granted approval of the Sentimag System to Endomagnetics Inc.

The  Endomagnetics' Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal.

Technology | Women's Health | July 24, 2018
July 24, 2018 — The U.S.
Overlay Init